FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally

FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year